BPI 002 is an oral, small-molecule, cytotoxic T-lymphocyte antigen 4 inhibitor (CTLA4 inhibitor), being developed by BeyondSpring as an immuno-oncology agent for the treatment of colon cancer and COVID-2019 infections. Preclinical development is underway in the US.
Key Development Milestones
In March 2020, BeyondSpring reported that BPI 002 can activate the adaptive immune system, including CD4+ helper T cells and CD8+ cytotoxic T cells, to directly attack and kill virally infected cells, including RNA virus, such as those causing COVID-2019. BPI 002 can also potentially function as an adjuvant to provide improved long-term humoral (B-cell dependent) protection against future viral infection, when combined with a vaccine.The company also mentioned that the drug has the potential to directly attack and kill RNA virus without precipitating thereby limiting toxicities  .
In preclinical studies in immune competent colon cancer animal model, BPI 002 was synergistic to checkpoint inhibitors  .
In March 2020, BeyondSpring reported that the company has submitted provisional U.S. patent application for its pipeline asset BPI-002, for methods of treating viral infections, including COVID-2019 inections, when administered alone or in combination with a vaccine  .
As at March 2017, BeyondSpring Pharma owned four pending international patent applications filed under the PCT, which the company planned to file nationally in the US and in other jurisdictions directed to compositions containing BPI 002 and methods of using BPI 002  .